Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223034 · ClinicalTrials.gov registry record · Phase 1
A Study of 177Lu-PSMA-617 in People With Gliomas
A Phase 1 study of Glioma and Glioblastoma, IDH-wildtype, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT07223034: Recruiting Phase 1 study of Glioma and Glioblastoma, IDH-wildtype, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07223034 is a Phase 1 study of Glioma and Glioblastoma, IDH-wildtype that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (90% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223034, a Phase 1 study of Glioma and Glioblastoma, IDH-wildtype, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
Primary Outcome
using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG 177Lu-PSMA-617
- DIAGNOSTIC_TEST 68Ga-PSMA-PET scan/ MRI
- BEHAVIORAL Quality of Life Questionnaires
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-10-27 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What NCT07223034 shows while recruiting
NCT07223034 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (90% lower).
The record links to 6 conditions, with Glioma appearing as the primary indexed condition, and to 4 interventions - of which Temozolomide is the first listed.
NCT07223034 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT07223034 about?
NCT07223034 is a clinical study titled "A Study of 177Lu-PSMA-617 in People With Gliomas". The researchers are doing this study to find out whether the radiopharmaceutical therapy (RPT) 177Lu-PSMA-617 is a safe treatment for people with IDH wild type glioma.
What is the current status of trial NCT07223034?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-10-27. Estimated completion is 2027-10.
What conditions does trial NCT07223034 study?
This clinical trial studies the following conditions: Glioma, Glioblastoma, IDH-wildtype, Diffuse Hemispheric Glioma, H3 G34-Mutant, Diffuse Midline Glioma, H3 K27-Altered, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4).
What interventions are being tested in trial NCT07223034?
The interventions under investigation include: Temozolomide (DRUG), 177Lu-PSMA-617 (DRUG), 68Ga-PSMA-PET scan/ MRI (DIAGNOSTIC_TEST), Quality of Life Questionnaires (BEHAVIORAL).
Who is sponsoring clinical trial NCT07223034?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223034 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07223034's enrollment target sits among peer trials
20 65th of 87 higher than 18 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
-
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI